Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Minister-backed Panel to Propose Policies to Promote Drug Discovery
September 3, 2001
- Antacids Are Most Expensive in Tokyo: Inter-city Comparison of OTC Drug Prices
September 3, 2001
- PMSB Considers Introduction of Drug Master File System
September 3, 2001
- Kirin-do to Strengthen Dispensing Function
September 3, 2001
- ADR Reports on 6 Drugs Including Temocapril HCl Published
September 3, 2001
- Jovi to Tie Up with CGC Japan
September 3, 2001
- 10 New Ingredients Added to NHI Price List
September 3, 2001
- Seijo to Tie Up with Fuji Yakuhin, Mine Yakuhin
September 3, 2001
- Time Clock from Development to Approval to Be Shortened to within 5 Years?
September 3, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 3, 2001
- BUSINESS NEWS IN BRIEF
September 3, 2001
- Korosho to Present Healthcare Reform Proposals in September
September 3, 2001
- Takeda, Bayer Decide to Recall Cerivastatin in Japan
September 3, 2001
- Bungyo Rate Increased to 43.5% in April: JPA
September 3, 2001
- Takeda Withdraws Calan
September 3, 2001
- JMA Research Institute Proposes Basic Policy for e-health
September 3, 2001
- Fukujin Ties Up with Kobayashi Daiyakubo
September 3, 2001
- Employees' Health Insurance Societies Have Assets of \5.2 Trillion: JMA
September 3, 2001
- Takeda Enters Top 10: Corporate Income Ranking
September 3, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
September 3, 2001
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…